Shah Gilani's got three stocks to sell immediately and one great stock to buy.
Moderna Inc
The Best Stock Trades to Make in the Market’s Hottest Sectors
Start the conversation
You must be logged in to post a comment.
Shah Gilani’s watching three companies this week in three of the market’s hottest sectors.
Plus, he’ll show you exactly how to play each one of them for some serious profit…
Moderna Stock Forecast 2025: 70% Gain in Five Years
Start the conversation
You must be logged in to post a comment.
The Moderna stock forecast from Wall Street would have you think this stock is overbought.
But there is more to Moderna stock than COVID vaccines…
Why Moderna Stock Is Still a Strong Buy Now
Start the conversation
You must be logged in to post a comment.
For months, biotech companies and government officials talked about eventually needing a coronavirus booster vaccine.
Now that the Delta variant accounts for 98.8% of new U.S. infections, the possibility of wheeling out a booster is more real.
Moderna stock (NASDAQ: MRNA) got a huge pop since rolling out its initial vaccines.
It's up 466%% year-over-year.
Now, investors hope another round of vaccine distributions may fuel the company's bottom line and translate to similar gains.
They could be right…
The One mRNA Vaccine Stock to Buy Today
Pfizer, BioNTech, and Moderna investors enjoyed massive gains from late 2020 to early 2021 as the "vaccine stocks" exploded in value as their product was authorized.
Here's the thing, though – the profits aren't finished.
One company is set to experience another round of big gains over the next year or more.
Michael A. Robinson has the ticker…
This Cheap Stock Opens up a $100 Billion Medical Market
Start the conversation
You must be logged in to post a comment.
Understandably, a lot of the world's medical and scientific firepower was focused on coronavirus vaccines this year.
But other advances in medicine have the potential to do even more for investors than the "vaccine stocks" did.
Shah's looking at a potential $100 billion medical market, and sizing up a $6 stock to play it…
How to Profit in a $29 Billion “New Biotech” Sector
Start the conversation
You must be logged in to post a comment.
Back in the late 1960s and early 1970s, psychedelics drugs like LSD were still legal and could be researched.
But in 1968 when the federal government criminalized them, a lot of promising research stopped.
Now the spotlight is back on these drugs and the success they’ve shown in clinical trials for treating a range of mental health conditions.
This is not only great news for people suffering from these conditions, but also for savvy investors who’ll get in on the ground floor of a market that could be worth more than $29 billion by the end of the decade.
Here’s Shah with all the details….
This Is the Perfect ETF for 300% Growth… and Wall Street Is Sleeping on It
Start the conversation
You must be logged in to post a comment.
Cathie Wood of ARK Investment Management is one of today’s savviest fund managers.
But she recently received some flak for making what Michael believes is one of her shrewdest investments yet in a sector likely to grow 300% to hit $82 billion in five years.
And what mainstream Wall Street is turning its nose up at could mean incredible profits for us….
This COVID-19 Vaccine Stock Has More Upside Than Pfizer or Moderna
Start the conversation
You must be logged in to post a comment.
Developing effective vaccines against a deadly global pandemic is certainly bullish for a stock.
Indeed, Moderna and Pfizer shareholders have put away as much as 516% and 51% gains, respectively.
And when a lot of investors see this, they fear they’ve missed out.
Well, Michael’s here to assure you that you haven’t; not by a long shot.
And today, he’s got a vaccine stock you should put at the top of your “must-buy” list for the week ahead… .
The Smart Way to Buy AAPL and MSFT… and Protect All Your Profits
As upbeat as the vaccine headlines have been recently, the virus and uncertainty over stimulus could send markets lower.
So, the smart move is to add to our positions in some of the year’s top tech performers (or any stock) with these two pro-level moves to “lock in” gains no matter what happens….
Start the conversation